Quantitative structural MRI for early detection of Alzheimer’s disease

References

• The Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement.6(2), 158–194 (2010).
   PubMed Web of Science ®Google Scholar
• Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin. Neurosci.11(2), 111–128 (2009).
   PubMedGoogle Scholar
• Ferri CP, Prince M, Brayne C et al. Global prevalence of dementia: a Delphi consensus study. Lancet366(9503), 2112–2117 (2005).
   PubMed Web of Science ®Google Scholar
• Rafii MS, Aisen PS. Recent developments in Alzheimer’s disease therapeutics. BMC Med.7, 7 (2009).
   PubMed Web of Science ®Google Scholar
• Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology69(16), 1622–1634 (2007).
   PubMed Web of Science ®Google Scholar
• Aisen PS. Commentary on “a roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” Facilitating Alzheimer’s disease drug development in the United States. Alzheimers Dement.5(2), 125–127 (2009).
   PubMedGoogle Scholar
• Ellis KA, Rowe CC, Villemagne VL et al. Addressing population aging and Alzheimer’s disease through the Australian imaging biomarkers and lifestyle study: collaboration with the Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dement.6(3), 291–296 (2010).
   PubMedGoogle Scholar
• Frisoni GB. Alzheimer’s disease neuroimaging initiative in Europe. Alzheimers Dement.6(3), 280–285 (2010).
   PubMedGoogle Scholar
• Iwatsubo T. Japanese Alzheimer’s Disease Neuroimaging Initiative: present status and future. Alzheimers Dement.6(3), 297–299 (2010).
   PubMedGoogle Scholar
• Weiner MW, Aisen PS, Jack CR Jr et al. The Alzheimer’s disease neuroimaging initiative: progress report and future plans. Alzheimers Dement.6(3), 202–211 e207 (2010).
   PubMed Web of Science ®Google Scholar
• Mueller SG, Weiner MW, Thal LJ et al. Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI). Alzheimers Dement.1(1), 55–66 (2005).
   PubMedGoogle Scholar
• Aisen PS, Petersen RC, Donohue MC et al. Clinical core of the Alzheimer’s Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement.6(3), 239–246 (2010).
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Bernstein MA, Borowski BJ et al. Update on the magnetic resonance imaging core of the Alzheimer’s disease neuroimaging initiative. Alzheimers Dement.6(3), 212–220 (2010).
   PubMed Web of Science ®Google Scholar
• Jagust WJ, Bandy D, Chen K et al. The Alzheimer’s Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement.6(3), 221–229 (2010).
   PubMed Web of Science ®Google Scholar
• Trojanowski JQ, Vandeerstichele H, Korecka M et al. Update on the biomarker core of the Alzheimer’s Disease Neuroimaging Initiative subjects. Alzheimers Dement.6(3), 230–238 (2010).
   PubMedGoogle Scholar
• Citron M. Alzheimer’s disease: strategies for disease modification. Nat. Rev. Drug Discov.9(5), 387–398 (2010).
   PubMed Web of Science ®Google Scholar
• Grill JD, Cummings JL. Current therapeutic targets for the treatment of Alzheimer’s disease. Expert Rev. Neurother.10(5), 711–728 (2010).
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Staging of Alzheimer-related cortical destruction. Int. Psychogeriatr.9(Suppl. 1), 257–261; discussion 269–272 (1997).
   PubMedGoogle Scholar
• Bennett DA, Schneider JA, Arvanitakis Z et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology66(12), 1837–1844 (2006).
   PubMed Web of Science ®Google Scholar
• Price JL, McKeel DW Jr, Buckles VD et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol. Aging30(7), 1026–1036 (2009).
   PubMed Web of Science ®Google Scholar
• Lee HG, Zhu X, Castellani RJ, Nunomura A, Perry G, Smith MA. Amyloid-β in Alzheimer disease: the null versus the alternate hypotheses. J. Pharmacol. Exp. Ther.321(3), 823–829 (2007).
   PubMed Web of Science ®Google Scholar
• Iqbal K, Grundke-Iqbal I. Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. J. Cell. Mol. Med.12(1), 38–55 (2008).
   PubMed Web of Science ®Google Scholar
• Castellani RJ, Lee HG, Siedlak SL et al. Reexamining Alzheimer’s disease: evidence for a protective role for amyloid-β protein precursor and amyloid-β. J. Alzheimers Dis.18(2), 447–452 (2009).
   PubMed Web of Science ®Google Scholar
• Pimplikar SW. Reassessing the amyloid cascade hypothesis of Alzheimer’s disease. Int. J. Biochem. Cell Biol.41(6), 1261–1268 (2009).
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. (Berl.)82(4), 239–259 (1991).
   PubMed Web of Science ®Google Scholar
• Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. (Berl.)112(4), 389–404 (2006).
   PubMed Web of Science ®Google Scholar
• McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34(7), 939–944 (1984).
   PubMed Web of Science ®Google Scholar
• Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol.6(8), 734–746 (2007).
   PubMed Web of Science ®Google Scholar
• Dubois B, Picard G, Sarazin M. Early detection of Alzheimer’s disease: new diagnostic criteria. Dialogues Clin. Neurosci.11(2), 135–139 (2009).
   PubMedGoogle Scholar
• Sarazin M, Berr C, De Rotrou J et al. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology69(19), 1859–1867 (2007).
   PubMed Web of Science ®Google Scholar
• Jacobson MW, McEvoy LK, Dale A, Fennema-Notestine C. Cognitive phenotypes, brain morphometry and the detection of cognitive decline in preclinical AD. Behav. Neurol.21(1), 29–37 (2009).
   PubMed Web of Science ®Google Scholar
• Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol.6(3), 131–144 (2010).
   PubMed Web of Science ®Google Scholar
• Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav. Neurol.21(1), 117–128 (2009).
   PubMed Web of Science ®Google Scholar
• Fennema-Notestine C, McEvoy LK, Hagler DJ Jr, Jacobson MW, Dale AM. The Alzheimer’s Disease Neuroimaging I. Structural neuroimaging in the detection and prognosis of pre-clinical and early AD. Behav. Neurol.21(1), 3–12 (2009).
   PubMed Web of Science ®Google Scholar
• Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat. Rev. Neurol.6(2), 67–77 (2010).
   PubMed Web of Science ®Google Scholar
• Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging32(4), 486–510 (2005).
   PubMed Web of Science ®Google Scholar
• Herholz K, Carter SF, Jones M. Positron emission tomography imaging in dementia. Br. J. Radiol.80(Spec. No. 2), S160–S167 (2007).
   Web of Science ®Google Scholar
• Petersen RC. Mild cognitive impairment as a diagnostic entity. J. Intern. Med.256(3), 183–194 (2004).
   PubMed Web of Science ®Google Scholar
• Petersen RC, Thomas RG, Grundman M et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med.352(23), 2379–2388 (2005).
   PubMed Web of Science ®Google Scholar
• Petersen RC, Aisen PS, Beckett LA et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology74(3), 201–209 (2010).
   PubMed Web of Science ®Google Scholar
• Carrillo MC, Blackwell A, Hampel H et al. Early risk assessment for Alzheimer’s disease. Alzheimers Dement.5(2), 182–196 (2009).
   PubMed Web of Science ®Google Scholar
• Larrieu S, Letenneur L, Orgogozo JM et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology59(10), 1594–1599 (2002).
   PubMed Web of Science ®Google Scholar
• Jicha GA, Parisi JE, Dickson DW et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch. Neurol.63(5), 674–681 (2006).
   PubMed Web of Science ®Google Scholar
• Mattsson N, Zetterberg H, Hansson O et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA302(4), 385–393 (2009).
   PubMed Web of Science ®Google Scholar
• Nordlund A, Rolstad S, Klang O, Edman A, Hansen S, Wallin A. Two-year outcome of MCI subtypes and aetiologies in the Goteborg MCI study. J. Neurol. Neurosurg. Psychiatry81(5), 541–546 (2010).
   PubMed Web of Science ®Google Scholar
• McEvoy LK, Edland SD, Holland D et al. Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease. Alzheimer Dis. Assoc. Disord.24(3), 269–277 (2010).
   PubMed Web of Science ®Google Scholar
• Fennema-Notestine C, Hagler DJ Jr, McEvoy LK et al. Structural MRI biomarkers for preclinical and mild Alzheimer’s disease. Hum. Brain Mapp.30(10), 3238–3253 (2009).
   PubMed Web of Science ®Google Scholar
• Morra JH, Tu Z, Apostolova LG et al. Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer’s disease, mild cognitive impairment, and elderly controls. Hum. Brain Mapp.30(9), 2766–2788 (2009).
   PubMed Web of Science ®Google Scholar
• Walhovd KB, Fjell AM, Dale AM et al. Multi-modal imaging predicts memory performance in normal aging and cognitive decline. Neurobiol. Aging31(7), 1107–1121 (2010).
   PubMed Web of Science ®Google Scholar
• Kovacevic S, Rafii MS, Brewer JB. High-throughput, fully automated volumetry for prediction of MMSE and CDR decline in mild cognitive impairment. Alzheimer Dis. Assoc. Disord.23(2), 139–145 (2009).
   PubMed Web of Science ®Google Scholar
• Ashburner J, Csernansky JG, Davatzikos C, Fox NC, Frisoni GB, Thompson PM. Computer-assisted imaging to assess brain structure in healthy and diseased brains. Lancet Neurol.2(2), 79–88 (2003).
   PubMed Web of Science ®Google Scholar
• Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc. Natl Acad. Sci. USA97(20), 11050–11055 (2000).
   PubMed Web of Science ®Google Scholar
• Fischl B, Salat DH, Busa E et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron33(3), 341–355 (2002).
   PubMed Web of Science ®Google Scholar
• Fischl B, Salat DH, van der Kouwe AJ et al. Sequence-independent segmentation of magnetic resonance images. Neuroimage23(Suppl. 1), S69–S84 (2004).
   PubMed Web of Science ®Google Scholar
• Fischl B, Van Der Kouwe A, Destrieux C et al. Automatically parcellating the human cerebral cortex. Cereb. Cortex14(1), 11–22 (2004).
   PubMed Web of Science ®Google Scholar
• Vemuri P, Gunter JL, Senjem ML et al. Alzheimer’s disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage39(3), 1186–1197 (2008).
   PubMedGoogle Scholar
• Dickerson BC, Bakkour A, Salat DH et al. The cortical signature of Alzheimer’s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb. Cortex19(3), 497–510 (2009).
   PubMed Web of Science ®Google Scholar
• McDonald CR, McEvoy LK, Gharapetian L et al. Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. Neurology73(6), 457–465 (2009).
   PubMed Web of Science ®Google Scholar
• Fan Y, Batmanghelich N, Clark CM, Davatzikos C. Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline. Neuroimage39(4), 1731–1743 (2008).
   PubMed Web of Science ®Google Scholar
• McEvoy LK, Fennema-Notestine C, Roddey JC et al. Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology251(1), 195–205 (2009).
   PubMed Web of Science ®Google Scholar
• Vemuri P, Wiste HJ, Weigand SD et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology73(4), 287–293 (2009).
   PubMed Web of Science ®Google Scholar
• Vemuri P, Whitwell JL, Kantarci K et al. Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage42(2), 559–567 (2008).
   PubMed Web of Science ®Google Scholar
• Whitwell JL, Josephs KA, Murray ME et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology71(10), 743–749 (2008).
   PubMedGoogle Scholar
• Du AT, Schuff N, Kramer JH et al. Different regional patterns of cortical thinning in Alzheimer’s disease and frontotemporal dementia. Brain130(Pt 4), 1159–1166 (2007).
   PubMed Web of Science ®Google Scholar
• Rabinovici GD, Seeley WW, Kim EJ et al. Distinct MRI atrophy patterns in autopsy-proven Alzheimer’s disease and frontotemporal lobar degeneration. Am. J. Alzheimers Dis. Other Demen.22(6), 474–488 (2007).
   PubMedGoogle Scholar
• Whitwell JL, Weigand SD, Shiung MM et al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer’s disease. Brain130(Pt 3), 708–719 (2007).
   PubMedGoogle Scholar
• Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron62(1), 42–52 (2009).
   PubMed Web of Science ®Google Scholar
• Bell-McGinty S, Lopez OL, Meltzer CC et al. Differential cortical atrophy in subgroups of mild cognitive impairment. Arch. Neurol.62(9), 1393–1397 (2005).
   PubMedGoogle Scholar
• Singh V, Chertkow H, Lerch JP, Evans AC, Dorr AE, Kabani NJ. Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer’s disease. Brain129(Pt 11), 2885–2893 (2006).
   PubMed Web of Science ®Google Scholar
• Whitwell JL, Shiung MM, Przybelski SA et al. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology70(7), 512–520 (2008).
   PubMed Web of Science ®Google Scholar
• Reisberg B, Gauthier S. Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer’s disease. Int. Psychogeriatr.20(1), 1–16 (2008).
   PubMed Web of Science ®Google Scholar
• Jessen F, Wiese B, Bachmann C et al. Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. Arch. Gen. Psychiatry67(4), 414–422 (2010).
   PubMed Web of Science ®Google Scholar
• Saykin AJ, Wishart HA, Rabin LA et al. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology67(5), 834–842 (2006).
   PubMed Web of Science ®Google Scholar
• Apostolova LG, Dutton RA, Dinov ID et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch. Neurol.63(5), 693–699 (2006).
   PubMedGoogle Scholar
• Apostolova LG, Mosconi L, Thompson PM et al. Subregional hippocampal atrophy predicts Alzheimer’s dementia in the cognitively normal. Neurobiol Aging31(7), 1077–1088 (2010).
   PubMed Web of Science ®Google Scholar
• Devanand DP, Pradhaban G, Liu X et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology68(11), 828–836 (2007).
   PubMed Web of Science ®Google Scholar
• Bakkour A, Morris JC, Dickerson BC. The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology72(12), 1048–1055 (2009).
   PubMed Web of Science ®Google Scholar
• Desikan RS, Cabral HJ, Fischl B et al. Temporoparietal MR imaging measures of atrophy in subjects with mild cognitive impairment that predict subsequent diagnosis of Alzheimer disease. AJNR Am. J. Neuroradiol.30(3), 532–538 (2009).
   PubMed Web of Science ®Google Scholar
• Vemuri P, Wiste HJ, Weigand SD et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology73(4), 294–301 (2009).
   PubMed Web of Science ®Google Scholar
• Davatzikos C, Fan Y, Wu X, Shen D, Resnick SM. Detection of prodromal Alzheimer’s disease via pattern classification of MRI. Neurobiol Aging29(4), 514–523 (2008).
   PubMed Web of Science ®Google Scholar
• McEvoy LK, Holland D, Hagler DJ Jr, Fennema-Notestine C, Dale AM. Structural neuroimaging for individual patient risk assessment in mild cognitive impairment. Alzheimers Dement.6(4 Suppl.), S300–S301 (2010).
   Google Scholar
• Jack CR Jr, Shiung MM, Weigand SD et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology65(8), 1227–1231 (2005).
   PubMed Web of Science ®Google Scholar
• Henneman WJ, Sluimer JD, Barnes J et al. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology72(11), 999–1007 (2009).
   PubMed Web of Science ®Google Scholar
• Schott JM, Price SL, Frost C, Whitwell JL, Rossor MN, Fox NC. Measuring atrophy in Alzheimer disease: a serial MRI study over 6 and 12 months. Neurology65(1), 119–124 (2005).
   PubMed Web of Science ®Google Scholar
• Ridha BH, Anderson VM, Barnes J et al. Volumetric MRI and cognitive measures in Alzheimer disease: comparison of markers of progression. J. Neurol.255(4), 567–574 (2008).
   PubMed Web of Science ®Google Scholar
• Barnes J, Bartlett JW, van de Pol LA et al. A meta-analysis of hippocampal atrophy rates in Alzheimer’s disease. Neurobiol. Aging30(11), 1711–1723 (2009).
   PubMed Web of Science ®Google Scholar
• Holland D, Brewer JB, Hagler DJ, Fenema-Notestine C, Dale AM. Subregional neuroanatomical change as a biomarker for Alzheimer’s disease. Proc. Natl Acad. Sci. USA106(49), 20954–20959 (2009).
   PubMed Web of Science ®Google Scholar
• McDonald CR, Gharapetian L, McEvoy LK et al. Relationship between regional atrophy rates and cognitive decline in mild cognitive impairment. Neurobiol. Aging DOI: 10.1016/j.neurobiolaging.2010.03.015 (2010) (Epub ahead of print).
   Google Scholar
• Ridha BH, Barnes J, Bartlett JW et al. Tracking atrophy progression in familial Alzheimer’s disease: a serial MRI study. Lancet Neurol.5(10), 828–834 (2006).
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Weigand SD, Shiung MM et al. Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology70(19 Pt 2), 1740–1752 (2008).
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Knopman DS, Jagust WJ et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol.9(1), 119–128 (2010).
   PubMed Web of Science ®Google Scholar
• Scahill RI, Fox NC. Longitudinal imaging in dementia. Br. J. Radiol.80(Spec. No. 2), S92–S98 (2007).
   Google Scholar
• Barnes J, Godbolt AK, Frost C et al. Atrophy rates of the cingulate gyrus and hippocampus in AD and FTLD. Neurobiol. Aging28(1), 20–28 (2007).
   PubMedGoogle Scholar
• Krueger CE, Dean DL, Rosen HJ et al. Longitudinal rates of lobar atrophy in frontotemporal dementia, semantic dementia, and Alzheimer’s disease. Alzheimer Dis. Assoc. Disord.24(1), 43–48 (2010).
   PubMedGoogle Scholar
• Fjell AM, Walhovd KB, Fennema-Notestine C et al. One-year brain atrophy evident in healthy aging. J. Neurosci.29(48), 15223–15231 (2009).
   PubMed Web of Science ®Google Scholar
• Murphy EA, Holland D, Donohue M et al. Six-month atrophy in MTL structures is associated with subsequent memory decline in elderly controls. Neuroimage53(4), 1310–1317 (2010).
   PubMed Web of Science ®Google Scholar
• Landau SM, Harvey D, Madison CM et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology75(3), 230–238 (2010).
   PubMed Web of Science ®Google Scholar
• Langbaum JB, Chen K, Caselli RJ et al. Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele. Arch. Neurol.67(4), 462–468 (2010).
   PubMedGoogle Scholar
• Karow DS, McEvoy LK, Fennema-Notestine C et al. Relative capability of MR Imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease . Radiology256(3), 932–942 (2010).
   PubMed Web of Science ®Google Scholar
• Villain N, Fouquet M, Baron JC et al. Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer’s disease. Brain doi: 10.1093/brain/awq203 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer’s disease. Alzheimers Dement.4(1), 38–48 (2008).
   PubMed Web of Science ®Google Scholar
• Blennow K, Zetterberg H. Cerebrospinal fluid biomarkers for Alzheimer’s disease. J. Alzheimers Dis.18(2), 413–417 (2009).
   PubMed Web of Science ®Google Scholar
• Shaw LM, Vanderstichele H, Knapik-Czajka M et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann. Neurol.65(4), 403–413 (2009).
   PubMed Web of Science ®Google Scholar
• Buerger K, Ewers M, Pirttila T et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain129(Pt 11), 3035–3041 (2006).
   PubMed Web of Science ®Google Scholar
• Strozyk D, Blennow K, White LR, Launer LJ. CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology60(4), 652–656 (2003).
   PubMed Web of Science ®Google Scholar
• Fagan AM, Mintun MA, Mach RH et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Ab42 in humans. Ann. Neurol.59(3), 512–519 (2006).
   PubMed Web of Science ®Google Scholar
• Ikonomovic MD, Klunk WE, Abrahamson EE et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain131(Pt 6), 1630–1645 (2008).
   PubMed Web of Science ®Google Scholar
• Fagan AM, Mintun MA, Shah AR et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer’s disease. EMBO Mol. Med.1(8–9), 371–380 (2009).
   PubMed Web of Science ®Google Scholar
• Morris JC, Roe CM, Grant EA et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol.66(12), 1469–1475 (2009).
   PubMed Web of Science ®Google Scholar
• De Meyer G, Shapiro F, Vanderstichele H et al. Diagnosis-independent alzheimer disease biomarker signature in cognitively normal elderly people. Arch. Neurol.67(8), 949–956 (2010).
   PubMed Web of Science ®Google Scholar
• Rowe CC, Ellis KA, Rimajova M et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging31(8), 1275–1283 (2010).
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Lowe VJ, Weigand SD et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain132(Pt 5), 1355–1365 (2009).
   PubMed Web of Science ®Google Scholar
• Fjell AM, Walhovd KB, Fennema-Notestine C et al. Brain atrophy in healthy aging is related to CSF levels of Aβ1–42. Cereb. Cortex20(9), 2069–2079 (2010).
   PubMedGoogle Scholar
• Fjell AM, Walhovd KB, Fennema-Notestine C et al. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer’s disease. J. Neurosci.30(6), 2088–2101 (2010).
   PubMedGoogle Scholar
• Desikan RS, Cabral HJ, Settecase F et al. Automated MRI measures predict progression to Alzheimer’s disease. Neurobiol. Aging31(8), 1364–1374 (2010).
   PubMedGoogle Scholar
• Brewer JB. Fully-automated volumetric MRI with normative ranges: translation to clinical practice. Behav. Neurol.21(1), 21–28 (2009).
   PubMed Web of Science ®Google Scholar
• Han X, Jovicich J, Salat D et al. Reliability of MRI-derived measurements of human cerebral cortical thickness: the effects of field strength, scanner upgrade and manufacturer. Neuroimage32, 180–194 (2006).
   PubMed Web of Science ®Google Scholar
• Jovicich J, Czanner S, Greve D et al. Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. Neuroimage30(2), 436–443 (2006).
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Bernstein MA, Fox NC et al. The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods. J. Magn. Reson. Imaging27(4), 685–691 (2008).
   PubMed Web of Science ®Google Scholar
• Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans. Med. Imaging17(1), 87–97 (1998).
   PubMed Web of Science ®Google Scholar
• White NW, Roddey C, Shankaranaraynan A et al. PROMO: real-time prospective motion correction in MRI using image-based tracking. Magn. Reson. Med.63(1), 91–105 (2010).
   PubMed Web of Science ®Google Scholar
• Brown TT, Kuperman JM, Erhart M et al. Prospective motion correction of high-resolution magnetic resonance imaging data in children. Neuroimage53(1), 139–145 (2010).
   PubMed Web of Science ®Google Scholar
• Dale AM, Sereno MI. Improved localization of cortical activity by combining EEG and MEG with MRI cortical surface reconstruction: A linear approach. J. Cognitive Neurosci.5, 162–176 (1993).
   PubMed Web of Science ®Google Scholar
• Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage9(2), 179–194 (1999).
   PubMed Web of Science ®Google Scholar
• Fischl B, Sereno MI, Dale AM. Cortical surface-based analysis. II: inflation, flattening, and a surface-based coordinate system. Neuroimage9(2), 195–207 (1999).
   PubMed Web of Science ®Google Scholar
• Brewer JB, Magda S, Airriess C, Smith ME. Fully-automated quantification of regional brain volumes for improved detection of focal atrophy in Alzheimer disease. AJNR Am. J. Neuroradiol.30(3), 578–580 (2009).
   PubMed Web of Science ®Google Scholar
• Schott JM, Frost C, Whitwell JL et al. Combining short interval MRI in Alzheimer’s disease: Implications for therapeutic trials. J. Neurol.253(9), 1147–1153 (2006).
   PubMedGoogle Scholar
• Saumier D, Aisen PS, Gauthier S et al. Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer’s disease: the ALZHEMED (Tramiprosate) experience. J. Nutr. Health Aging13(4), 370–372 (2009).
   PubMed Web of Science ®Google Scholar
• Hua X, Lee S, Yanovsky I et al. Optimizing power to track brain degeneration in Alzheimer’s disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects. Neuroimage48(4), 668–681 (2009).
   PubMedGoogle Scholar
• Gauthier S, Aisen PS, Ferris SH et al. Effect of tramiprosate in patients with mild-to-moderate Alzheimer’s disease: exploratory analyses of the MRI sub-group of the Alphase study. J. Nutr. Health Aging13(6), 550–557 (2009).
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Gilman S et al. A Phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology73(24), 2061–2070 (2009).
   PubMed Web of Science ®Google Scholar
• Fox NC, Black RS, Gilman S et al. Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology64(9), 1563–1572 (2005).
   PubMed Web of Science ®Google Scholar
• Black RS, Sperling RA, Safirstein B et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis. Assoc. Disord.24(2), 198–203 (2010).
   PubMed Web of Science ®Google Scholar
• Panza F, Frisardi V, Imbimbo BP et al. γ-secretase inhibitors for the treatment of Alzheimer’s disease: the current state. CNS Neurosci. Ther. DOI: 10.1111/j.1755-5949.2010.00164.x (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Li H, Wolfe MS, Selkoe DJ. Toward structural elucidation of the γ-secretase complex. Structure17(3), 326–334 (2009).
   PubMed Web of Science ®Google Scholar